Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Inhibiting and Remodeling Toxic Amyloid-Beta Oligomer Formation Using a Computationally Designed Drug Molecule That Targets Alzheimer's Disease.

Downey MA, Giammona MJ, Lang CA, Buratto SK, Singh A, Bowers MT.

J Am Soc Mass Spectrom. 2019 Jan;30(1):85-93. doi: 10.1007/s13361-018-1975-1. Epub 2018 Apr 30. Erratum in: J Am Soc Mass Spectrom. 2019 Mar;30(3):561.

PMID:
29713966
2.

Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.

Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, Fillit H, Hey JA.

CNS Drugs. 2017 Jun;31(6):495-509. doi: 10.1007/s40263-017-0434-z.

3.

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.

Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhnálek M, Yu JY, Tolar M.

CNS Drugs. 2018 Sep;32(9):849-861. doi: 10.1007/s40263-018-0554-0. Erratum in: CNS Drugs. 2018 Dec;32(12):1185.

4.

Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo.

Hong HS, Rana S, Barrigan L, Shi A, Zhang Y, Zhou F, Jin LW, Hua DH.

J Neurochem. 2009 Feb;108(4):1097-1108. doi: 10.1111/j.1471-4159.2008.05866.x.

5.

Z-Phe-Ala-diazomethylketone (PADK) disrupts and remodels early oligomer states of the Alzheimer disease Aβ42 protein.

Zheng X, Gessel MM, Wisniewski ML, Viswanathan K, Wright DL, Bahr BA, Bowers MT.

J Biol Chem. 2012 Feb 24;287(9):6084-8. doi: 10.1074/jbc.C111.328575. Epub 2012 Jan 17.

6.
7.

Mechanism of C-Terminal Fragments of Amyloid β-Protein as Aβ Inhibitors: Do C-Terminal Interactions Play a Key Role in Their Inhibitory Activity?

Zheng X, Wu C, Liu D, Li H, Bitan G, Shea JE, Bowers MT.

J Phys Chem B. 2016 Mar 3;120(8):1615-23. doi: 10.1021/acs.jpcb.5b08177. Epub 2015 Oct 16.

8.

Ion mobility spectrometry reveals the mechanism of amyloid formation of Aβ(25-35) and its modulation by inhibitors at the molecular level: epigallocatechin gallate and scyllo-inositol.

Bleiholder C, Do TD, Wu C, Economou NJ, Bernstein SS, Buratto SK, Shea JE, Bowers MT.

J Am Chem Soc. 2013 Nov 13;135(45):16926-37. doi: 10.1021/ja406197f. Epub 2013 Nov 1.

PMID:
24131107
9.

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.

Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM.

J Biol Chem. 2005 Feb 18;280(7):5892-901. Epub 2004 Dec 7.

10.

Understanding amyloid fibril nucleation and aβ oligomer/drug interactions from computer simulations.

Nguyen P, Derreumaux P.

Acc Chem Res. 2014 Feb 18;47(2):603-11. doi: 10.1021/ar4002075. Epub 2013 Dec 24. Review.

PMID:
24368046
11.

Trodusquemine enhances Aβ42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes.

Limbocker R, Chia S, Ruggeri FS, Perni M, Cascella R, Heller GT, Meisl G, Mannini B, Habchi J, Michaels TCT, Challa PK, Ahn M, Casford ST, Fernando N, Xu CK, Kloss ND, Cohen SIA, Kumita JR, Cecchi C, Zasloff M, Linse S, Knowles TPJ, Chiti F, Vendruscolo M, Dobson CM.

Nat Commun. 2019 Jan 15;10(1):225. doi: 10.1038/s41467-018-07699-5.

12.

The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease.

Savelieff MG, DeToma AS, Derrick JS, Lim MH.

Acc Chem Res. 2014 Aug 19;47(8):2475-82. doi: 10.1021/ar500152x. Epub 2014 Jul 31.

PMID:
25080056
13.

Ferulic acid inhibits the transition of amyloid-β42 monomers to oligomers but accelerates the transition from oligomers to fibrils.

Cui L, Zhang Y, Cao H, Wang Y, Teng T, Ma G, Li Y, Li K, Zhang Y.

J Alzheimers Dis. 2013;37(1):19-28. doi: 10.3233/JAD-130164.

PMID:
23727899
14.

Design of LVFFARK and LVFFARK-functionalized nanoparticles for inhibiting amyloid β-protein fibrillation and cytotoxicity.

Xiong N, Dong XY, Zheng J, Liu FF, Sun Y.

ACS Appl Mater Interfaces. 2015 Mar 18;7(10):5650-62. doi: 10.1021/acsami.5b00915. Epub 2015 Mar 3.

PMID:
25700145
15.

Keampferol-3-O-rhamnoside abrogates amyloid beta toxicity by modulating monomers and remodeling oligomers and fibrils to non-toxic aggregates.

Sharoar MG, Thapa A, Shahnawaz M, Ramasamy VS, Woo ER, Shin SY, Park IS.

J Biomed Sci. 2012 Dec 21;19:104. doi: 10.1186/1423-0127-19-104.

16.

Capping of aβ42 oligomers by small molecule inhibitors.

Fu Z, Aucoin D, Ahmed M, Ziliox M, Van Nostrand WE, Smith SO.

Biochemistry. 2014 Dec 23;53(50):7893-903. doi: 10.1021/bi500910b. Epub 2014 Dec 11.

17.

Resting microglia react to Aβ42 fibrils but do not detect oligomers or oligomer-induced neuronal damage.

Ferrera D, Mazzaro N, Canale C, Gasparini L.

Neurobiol Aging. 2014 Nov;35(11):2444-2457. doi: 10.1016/j.neurobiolaging.2014.05.023. Epub 2014 May 29.

PMID:
24973120
18.

Structure-activity relationships for a series of compounds that inhibit aggregation of the Alzheimer's peptide, Aβ42.

McKoy AF, Chen J, Schupbach T, Hecht MH.

Chem Biol Drug Des. 2014 Nov;84(5):505-12. doi: 10.1111/cbdd.12341. Epub 2014 May 21.

19.

Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone: Insight into mechanism of action.

Sharma S, Nehru B, Saini A.

Neurochem Int. 2017 Sep;108:481-493. doi: 10.1016/j.neuint.2017.06.011. Epub 2017 Jun 24.

PMID:
28652220
20.

A novel inhibitor of amyloid β (Aβ) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease.

McKoy AF, Chen J, Schupbach T, Hecht MH.

J Biol Chem. 2012 Nov 9;287(46):38992-9000. doi: 10.1074/jbc.M112.348037. Epub 2012 Sep 19.

Supplemental Content

Support Center